Join the Lung Cancer group to help and get support from people like you.
Lung Cancer News (Page 6)
Related terms: Cancer, Bronchogenic Carcinoma, Cancer, Lung
FDA Approves Genentech’s Cancer Immunotherapy Tecentriq (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer
South San Francisco, CA – October 18, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Expands Use of Xalkori (crizotinib) to Treat ROS-1 Positive Non-Small Cell Lung Cancer
March 11, 2016 – The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1...
FDA Approves Keytruda (pembrolizumab) for Advanced Non-Small Cell Lung Cancer
October 2, 2015 – The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer...
FDA Approves Iressa (gefitinib) for First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
July 13, 2015 – The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors...
FDA Expands Approved use of Opdivo (nivolumab) to Treat Lung Cancer
March 4, 2015 – The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC)...
FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer
April 29, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung...
FDA Approves Gilotrif for Late Stage Non-Small Cell Lung Cancer
July 12, 2013 – The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific...
FDA Approves Xalkori with Companion Diagnostic for a Type of Late-Stage Lung Cancer
August 26, 2011 - The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers...
Ask a question
To post your own question to this support group, sign in or create an account.